The shorter timeline to risk and the reduction of shared savings rates are among the 2 greatest challenges accountable care organizations (ACOs) will face as part of the proposed changes to the Medicare Shared Savings Program (MSSP), said Allison Brennan, MPP, senior vice president of government affairs for the National Association of ACOs.
The shorter timeline to risk and the reduction of shared savings rates are among the 2 greatest challenges accountable care organizations (ACOs) will face as part of the proposed changes to the Medicare Shared Savings Program (MSSP), said Allison Brennan, MPP, senior vice president of government affairs for the National Association of ACOs.
Transcript
What is the greatest challenge you see as part of the proposed MSSP changes?
I think the greatest challenges that we see are, number 1, the shortening of time that new ACOs have before they have to take on risk. Currently, in the program, new ACOs have 6 years before they’re required to take on risk. Even at the end of 6 years at lot of ACOs find that challenging. This proposal would shorten that time frame down to 2 years, and when we say 2 years it’s also important to note that that really only means that ACOs have only 1 year of performance results. So, essentially, it’s like they’re flying blind to make this big leap. They only have a little bit of data and performance to go on before they move into a risk-based model.
Another really significant challenge that we see in the regulation is the proposal to cut in half the shared savings rates for ACOs. Right now, if ACOs meet the requirements in and they’re eligible to share in savings for the government, they get to keep 50% of that savings. Under the proposal they would only get to keep 25% of the savings. When we’re looking at the investments ACOs are making, upfront, which are not counted in the calculations of risk from CMS, they’re looking at a return on investment that’s now being cut in half. And that’s really just a nonstarter for a lot of ACOs. They just don’t think that’s a viable business model with shared savings rates that low.
A couple other challenges that we see in the regulation, there’s a proposal to introduce the distinction among ACOs kind of along hospital versus physician-led lines and we have some concerns about that proposal and would like to see ACOs being treated, kind of, fairly across the board.
Finally, I would say there is a proposal that would terminate ACOs from their program if their spending is a little than projected, and this is under the guise of program integrity, but we really don’t think this is a program integrity proposal. It’s really just looking at spending being slightly different than the benchmark. So, that’s something we’re very concerned about and will be opposing.
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most
March 13th 2025On December 10, 2024, cardiologists, researchers, and value-based care experts gathered in Dallas, Texas, to discuss best practices for implementing advances in cardiology care with a value-based mindset, spanning the care continuum from prevention to treatment.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More
Late-Breaking Antiviral Session Features Phase 3 Results on Efficacy of Doravirine/Islatravir
March 13th 2025The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.
Read More